PACTR202101544570971尚未招募3 期
Prevention and Treatment of COVID19 Associated Severe Pneumonia in The Gambia: A single blind - Randomized Trial COVID-19
Medical Research Council Unit The Gambia at LSHTM0 个研究点目标入组 1,200 人开始时间: 2020年10月27日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 12 Year(s)（—）
- 性别
- All
入选标准
- •Individuals = 5 years of age with confirmed COVID19 mild disease or moderate pneumonia defined as: - Mild disease - Influenzae like illness, with any of the following symptoms cough, fever, headache, sore throat, nasal congestion/runny nose, body pains (myalgia), fatigue (malaise), diarrhea, abdominal pain, anorexia, nausea or vomiting without evidence of pneumonia or hypoxia - Moderate pneumonia –Clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) with no need for supplemental oxygen (oxygen saturation =90%% on room air or RR between 20 and 30bpm). HH members from Cohort 1 – Individuals > 5 year of age living in the same HH with the index cases from cohort 1 will be offered to participate into the study. Living in the same HH is defined as those individuals who are planning to sleep in and eat from same compound during the following 2 weeks
- •Individuals =12 years of age with suspected or confirmed COVID-19 associated severe pneumonia defined as signs of pneumonia (fever, cough, dyspnoea or fast breathing) plus one of: oxygen saturation (SpO2) <90% on room air OR respiratory rate > 30 breaths/minute Suspected COVID-19 disease is defined as clinically or radiologically suspected as determined by the most senior clinician available:
- •1. Clinically suspected
- •Signs and symptoms of pneumonia (as defined above)
- •AND patient living in or recent travel to region with community transmission OR close contact with known COVID-19 patient
- •AND no alternative diagnosis to explain the clinical picture
- •2. Radiologically suspected
- •Typical radiological signs of COVID-19 on chest X-ray or lung ultrasound
排除标准
- •Pregnant women will be excluded from both Cohort 1 if the drug is IVM and . Individuals will be excluded into the study if: - Known contra-indication or allergy to study drugs
- •If the drug is Aspirin. Individuals will be excluded into the study if: - Known contra-indication or allergy to study drugs Some clinical characteristics will exclude participants from some of the severe pneumonia arms:
- •PaTS-COVID Trial: Protocol Version 1.3_17 August 2020
- •o Patients already on steroids will be excluded from the dexamethasone arm if applicable o Active untreated or inactive tuberculosis for the deaxamethasone arm if applicable o Known bleeding disorder for aspirin if applicable o Prolonged QTc – excluded from azithromycin if applicable
研究者
相似试验
招募中
3 期
Effect of ethanol and DMSO in prophylaxis and treatment of COVID-19IRCT20200727048217N1Shahroud University of Medical Sciences610
已完成
不适用
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trialCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000557932AProf Dr Karin Ried446
招募中
1 期
Therapies to prevent progression of COVID-19 in outpatients: The 'Primary Care Australian COVID-19 Therapeutics' (PACT) TrialACTRN12622000386730AProf Dr Karin Ried300
撤回
不适用
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trial - Stage 2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000309785AProf Dr Karin Ried200
进行中（未招募）
2 期
COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trialCOVID-19JPRN-jRCTs041200072Ogawa Keiko100